India's Cipla Unwraps Its Biosimilars Ambitions With A Presence In India And Shanghai; Earmarks $65 Million In First Push
MUMBAI - Many months after keeping its biosimilars plans under wraps, Cipla - India's second-largest drug maker - shared some parts of its proposed big picture that revolves around a manufacturing site in Goa, India, and another firm in Hong Kong that is putting up a biologics manufacturing facility in Shanghai
More from Archive
More from Scrip
Lead drug GLM101 will move into its first placebo-controlled trial based on positive results in adults and adolescents with PMM2-CDG in an open-label Phase IIa study.
The company is planning to start a registrational program on its home turf in Australia and is planning to bring the therapy to the US as well.
Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.